Anil Budania, Saptarshi Mandal, Yashdeep Singh Pathania, Utkrist Lahoria, Md Atik Khan, Inder Puri, Richa Mishra
Journal: Journal of cosmetic dermatology 2021;20(10):3245-3252
PMID: 33793043
BACKGROUND
Platelet-rich plasma (PRP) has been found to be effective in treating periorbital hyperpigmentation (POH). PRP prepared by double-spin (DS) method and activated by calcium has been used conventionally. PRP can be prepared by single spin (SS) and activated at low temperature (novel method), but the evidence is limited.
OBJECTIVE
To compare the novel and conventional PRP in the treatment of periorbital hyperpigmentation.
METHODS
We selected 21 patients of POH and randomly divided the face into two halves. One-half of the face (group A) was treated with novel PRP (SS and low-temperature activation). The other half (group B) was treated with conventional PRP (DS and calcium activation). A total of 3 PRP injections were given at 4 weekly intervals. Patients were observed and assessed on 12 week by photography, dermoscopy, visual analog scale (VAS) score, and Dermatology life quality index (DLQI). Platelet counts and growth factors were assessed in PRP.
RESULTS
Mean platelet count in novel and conventional PRP was 7.41 ± 1.76 lacs and 8.17 ± 2.23 lacs (p = 0.348). Mean photographic and dermoscopic assessment at the end of the study in group A and group B was 52.33 ± 6.468 and 53.14 ± 6.99 (p = 0.151). Change in VAS in groups A and B was 3.85 ± 1.27 and 3.90 ± 1.04 (p = 0.895). Levels of various growth factors assessed by ELISA did not differ significantly. There was significant decline in DLQI.
CONCLUSION
The novel method is not inferior to conventional method of PRP in the treatment of periorbital hyperpigmentation.
© 2021 Wiley Periodicals LLC.
Other Literature Sources:
Miscellaneous:
Research Materials:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.